JP2022537994A5 - - Google Patents

Info

Publication number
JP2022537994A5
JP2022537994A5 JP2021575050A JP2021575050A JP2022537994A5 JP 2022537994 A5 JP2022537994 A5 JP 2022537994A5 JP 2021575050 A JP2021575050 A JP 2021575050A JP 2021575050 A JP2021575050 A JP 2021575050A JP 2022537994 A5 JP2022537994 A5 JP 2022537994A5
Authority
JP
Japan
Prior art keywords
disease
formula
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021575050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537994A (ja
JP7618597B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/068181 external-priority patent/WO2021001286A1/en
Publication of JP2022537994A publication Critical patent/JP2022537994A/ja
Publication of JP2022537994A5 publication Critical patent/JP2022537994A5/ja
Application granted granted Critical
Publication of JP7618597B2 publication Critical patent/JP7618597B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021575050A 2019-07-01 2020-06-29 Ｄ１ポジティブアロステリックモジュレーターとしての置換されたテトラヒドロイソキノリン誘導体 Active JP7618597B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183641 2019-07-01
EP19183641.0 2019-07-01
PCT/EP2020/068181 WO2021001286A1 (en) 2019-07-01 2020-06-29 A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator

Publications (3)

Publication Number Publication Date
JP2022537994A JP2022537994A (ja) 2022-08-31
JP2022537994A5 true JP2022537994A5 (https=) 2023-07-04
JP7618597B2 JP7618597B2 (ja) 2025-01-21

Family

ID=67137842

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021575050A Active JP7618597B2 (ja) 2019-07-01 2020-06-29 Ｄ１ポジティブアロステリックモジュレーターとしての置換されたテトラヒドロイソキノリン誘導体

Country Status (24)

Country Link
US (1) US12358890B2 (https=)
EP (1) EP3993795B1 (https=)
JP (1) JP7618597B2 (https=)
KR (1) KR102949226B1 (https=)
CN (1) CN114008032B (https=)
AR (1) AR119317A1 (https=)
AU (1) AU2020299705B2 (https=)
BR (1) BR112021022379A2 (https=)
CA (1) CA3139622A1 (https=)
CL (1) CL2021002949A1 (https=)
CO (1) CO2021017740A2 (https=)
EC (1) ECSP22007557A (https=)
IL (1) IL289317B2 (https=)
MA (1) MA56445A (https=)
MX (1) MX2021015872A (https=)
MY (1) MY210362A (https=)
PE (1) PE20220373A1 (https=)
PH (1) PH12021552819A1 (https=)
SA (1) SA521431274B1 (https=)
SG (1) SG11202112539XA (https=)
TW (1) TWI842923B (https=)
UA (1) UA130613C2 (https=)
WO (1) WO2021001286A1 (https=)
ZA (1) ZA202109194B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2976784T3 (es) 2020-10-07 2024-08-08 Lilly Co Eli Derivados de fenil-3,4-dihidroisoquinolin-2(1H)-il-etan-1-ona como moduladores alostéricos positivos del receptor de dopamina D1
EP4304577A1 (en) * 2021-03-09 2024-01-17 Eli Lilly And Co. Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2679735A1 (en) 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
IN2014CN03234A (https=) 2011-11-03 2015-07-03 Merck Sharp & Dohme
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
WO2016055479A1 (en) 2014-10-08 2016-04-14 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
CN108884050B (zh) * 2016-04-13 2022-07-05 Ucb生物制药私人有限公司 四氢异喹啉衍生物
JP7090099B2 (ja) * 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑

Similar Documents

Publication Publication Date Title
JP2022539152A5 (https=)
US10526303B2 (en) 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
ES2261234T3 (es) Metabolitos de bupropion y metodos de sintesis y uso.
CA2528160A1 (en) Use of 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine for neuronal regeneration and functional recovery
JP2026035701A5 (https=)
JP2022537994A5 (https=)
JP2002501025A5 (https=)
JP2009511568A5 (https=)
WO2008011478A2 (en) Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
JP2012530779A5 (https=)
JP2004534816A5 (https=)
JP2013536833A5 (https=)
RU2010129929A (ru) Производные 5-оксо-3-пирролидинкарбоксамида в качестве модуляторов р2х7
JP2019512469A5 (https=)
TW201622721A (zh) Ｓ１ｐ調節劑之立即釋放劑量療法
JP2010513250A5 (https=)
JP2016537432A5 (https=)
JP2021530543A5 (https=)
JP2005508872A5 (https=)
JP2001523716A5 (https=)
CO6290669A2 (es) Usos terapeuticos de compuestos que tiene afinidad con el transportador de serotonina los receptores de serotonina y transportador de noraadrenalina
HRP20241657T1 (hr) Supstituirani derivat tetrahidroizokinolina kao d1 pozitivni alosterički modulator
JP2023518640A5 (https=)
RU2022101513A (ru) Замещенное производное тетрагидроизохинолина как позитивный аллостерический модулятор d1
RU2022101512A (ru) Замещенное производное тетрагидроизохинолина, как позитивный аллостерический модулятор d1